

UCSF

UC San Francisco Previously Published Works

Title

Changing Molecular Markers of Antimalarial Drug Sensitivity across Uganda

Permalink

<https://escholarship.org/uc/item/63c0027f>

Journal

Antimicrobial Agents and Chemotherapy, 63(3)

ISSN

0066-4804

Authors

Asua, Victor

Vinden, Joanna

Conrad, Melissa D

et al.

Publication Date

2019-03-01

DOI

10.1128/aac.01818-18

Peer reviewed



Changing Molecular Markers of Antimalarial Drug Sensitivity across Uganda

Victor Asua,^a Joanna Vinden,^b Melissa D. Conrad,^c Jennifer Legac,^c Simon P. Kigozi,^{a,d} Moses R. Kanya,^{a,e} Grant Dorsey,^c Samuel L. Nsoby,^{a,f} Philip J. Rosenthal^c

^aInfectious Diseases Research Collaboration, Kampala, Uganda

^bSchool of Public Health Division of Infectious Disease and Vaccinology, University of California, Berkeley, Berkeley, California, USA

^cDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA

^dDepartment of Disease Control, London School of Hygiene & Tropical Medicine, London, United Kingdom

^eSchool of Medicine, Makerere University College of Health Sciences, Kampala, Uganda

^fDepartment of Pathology, Makerere University College of Health Sciences, Kampala, Uganda

ABSTRACT The potential spread of antimalarial drug resistance to Africa, in particular for artemisinins and key partner drugs, is a major concern. We surveyed *Plasmodium falciparum* genetic markers associated with drug sensitivity on 3 occasions at ~6-month intervals in 2016 and 2017 at 10 sites representing a range of epidemiological settings in Uganda. For putative drug transporters, we found continued evolution toward wild-type sequences associated with increased sensitivity to chloroquine. For *pfcr1* K76T, by 2017 the prevalence of the wild type was >60% at all sites and >90% at 6 sites. For the *pfmdr1* N86Y and D1246Y alleles, wild type prevalence ranged from 80 to 100%. We found low prevalence of *K13* propeller domain mutations, which are associated with artemisinin resistance in Asia, but one mutation previously identified in northern Uganda, 675V, was seen in 2.0% of samples, including 5.5% of those from the 3 northernmost sites. Amplification of the *pfmdr1* and *plasmepsin2* genes, associated elsewhere with decreased sensitivity to lumefantrine and piperazine, respectively, was seen in <1% of samples. For the antifolate targets *pfdhfr* and *pfdhps*, 5 mutations previously associated with resistance were very common, and the *pfdhfr* 164L and *pfdhps* 581G mutations associated with higher-level resistance were seen at multiple sites, although prevalence did not clearly increase over time. Overall, changes were consistent with the selective pressure of the national treatment regimen, artemether-lumefantrine, with increased sensitivity to chloroquine, and with poor efficacy of antifolates. Strong evidence for resistance to artemisinins was not seen. Continued surveillance of markers that predict antimalarial drug sensitivity is warranted.

KEYWORDS Uganda, antimalarial drug sensitivity, molecular markers

Antimalarial drug resistance is a major concern. In Africa, resistance to chloroquine and antifolates has been widespread for many years (1). In Uganda, the standard therapy for uncomplicated malaria changed from chloroquine to chloroquine plus sulfadoxine-pyrimethamine (SP) in 2000 and then to the artemisinin-based combination therapy (ACT) artemether-lumefantrine in 2004, although implementation of the new regimen was slow (2). Many countries in Africa utilize the ACT artesunate-amodiaquine as first-line therapy. Dihydroartemisinin-piperazine is an alternative ACT for uncomplicated malaria in some countries and is under evaluation for chemoprevention (3). Amodiaquine plus SP is used for seasonal malaria chemoprevention in parts of west and central Africa (4). SP is the standard for intermittent preventive therapy during pregnancy (IPTp) (5). Resistance to each component of these regimens has been

Citation Asua V, Vinden J, Conrad MD, Legac J, Kigozi SP, Kanya MR, Dorsey G, Nsoby SL, Rosenthal PJ. 2019. Changing molecular markers of antimalarial drug sensitivity across Uganda. *Antimicrob Agents Chemother* 63:e01818-18. <https://doi.org/10.1128/AAC.01818-18>.

Copyright © 2019 American Society for Microbiology. All Rights Reserved.

Address correspondence to Philip J. Rosenthal, philip.rosenthal@ucsf.edu.

Received 27 August 2018

Returned for modification 17 October 2018

Accepted 6 December 2018

Accepted manuscript posted online 17 December 2018

Published 26 February 2019

detected (6) and the spread of resistance to Africa, in particular that to artemisinins and key partner drugs, may have devastating consequences.

Mechanisms of altered sensitivity to a number of antimalarial drugs are quite well understood. Mutations in genes encoding two putative drug transporters, *Plasmodium falciparum* multidrug resistance protein-1 (*pfmdr1*) and *P. falciparum* chloroquine resistance transporter (*pfcr1*), impact sensitivities to a number of drugs (1). Three mutations that have been common in Uganda, *pfcr1* 76T, *pfmdr1* 86Y, and *pfmdr1* 1246Y (7), are selected by therapy with artesunate-amodiaquine (8, 9) and associated with decreased sensitivity to aminoquinolines (10). Wild-type sequences at these same alleles are selected by prior therapy with artemether-lumefantrine (11–13), associated with decreased lumefantrine sensitivity (10), and, in a pooled analysis, predicted recrudescence after treatment with artemether-lumefantrine (14).

P. falciparum resistance to artemisinin derivatives, defined as delayed parasite clearance either clinically (15) or in the *in vitro* ring stage survival assay (16), is now widespread in southeast Asia (17, 18). This phenotype is associated with a number of different mutations in the propeller domain of the kelch13 (*K13*) protein (19). To date, 20 *K13* propeller domain mutations in Asia have been associated with delayed clearance (20). *K13* mutations have also been seen in *P. falciparum* isolates from Africa; most of these differ from the mutations associated with delayed clearance, and, based on clinical, parasitological, and molecular data, artemisinin resistance has not clearly been identified in Africa (21–25). Resistance to ACT partner drugs is also of great concern. In southeast Asia resistance to mefloquine, mediated by increased *pfmdr1* copy number (26), and to piperazine, mediated by increased *plasmepsin2* copy number (27, 28), has been noted. Furthermore, combined resistance to artemisinins and piperazine that has led to very high rates of treatment failure for dihydroartemisinin-piperazine in Cambodia is a concern (29, 30).

P. falciparum resistance to SP is mediated by mutations in the target dihydrofolate reductase (*pfdhfr*) and dihydropteroate synthase (*pfdhps*) genes (31). The combination of three mutations in *pfdhfr* (51I, 59R, and 108N) and two in *pfdhps* (437G and 540E) leads to an intermediate level of SP resistance (32). This genotype is common in Uganda and other parts of Africa, although the *pfdhps* 540E mutation is absent in much of west and central Africa (33). Addition of either *pfdhfr* 164L or *pfdhps* 581G leads to higher-level SP resistance (31). These additional mutations have been uncommon in Africa, but some reports have noted moderate prevalence of the *pfdhfr* 164L mutation in parasites from southwestern Uganda (34–36) and of the *pfdhps* 581G mutation in parasites from Uganda and Tanzania (35–37).

Changes in treatment practices appear to have impacted antimalarial drug sensitivity in Africa. In the clearest demonstration of this phenomenon, nonuse of chloroquine in Malawi in the 1990s was followed by reversion of parasites to the wild-type *pfcr1* K76 genotype, with subsequent demonstration of improved chloroquine sensitivity *in vitro* (38) and *in vivo* (39). In Uganda, with increased use of artemether-lumefantrine and decreased use of chloroquine to treat malaria, parasite genotypes have been changing, with increased prevalence of *pfcr1* and *pfmdr1* wild-type alleles (7, 35). Recently, high prevalence of wild-type *pfcr1* K76 parasites and remarkable improvement in *in vitro* sensitivity to chloroquine was observed in Tororo in eastern Uganda (10). Changing parasite sensitivities appear to have clinical consequences, with the efficacy of artesunate-amodiaquine being better than that of artemether-lumefantrine in recent trials, a change from the results of trials conducted about a decade ago (21, 40). For antifolates, resistance-associated mutations are widespread, but SP remains the standard of care for IPTp, and there is concern for selection of more highly resistant parasites. With this background, careful surveillance for established markers of antimalarial drug resistance is a high priority, and so we surveyed the prevalence of key polymorphisms over time at 10 sites across Uganda.




FIG 1 Surveillance sites in Uganda. The map shows study sites and estimated parasite prevalence for children 2 to 10 years of age. Estimates are based on community surveys between 1985 and 2010 under the Malaria Atlas Project. White locations have indeterminate prevalence based on insufficient data; these are primarily high-elevation areas with known low malaria transmission intensity.

RESULTS

Collection of samples. We set out to collect blood samples from 50 children presenting with malaria at each of 10 sites (Fig. 1) on 3 occasions during 2016 and 2017. A total of 1,459 samples were collected, as follows: 499 from April to June 2016 (collection 1), 491 from November 2016 to January 2017 (collection 2), and 469 from May to June 2017 (collection 3; Table S1); for Kabale, the third collection continued to October 2017 due to the low number of available samples. Fewer than 50 samples per collection were available from Kabale and Tororo during some collection periods due to low incidence of malaria (Table S1). Due to anticipated low prevalence of polymorphisms, sequencing of *K13* and assays for amplification of *pfmdr1* and *plasmepsin2* were only performed on samples from 2017; due to slow collection, these assays were not performed on samples from Kabale. Reported results are for samples that yielded data for at least one polymorphism.

Prevalence of drug resistance-mediating polymorphisms in putative transporters. The prevalence of key *pfcr* and *pfmdr1* polymorphisms varied across the country, but the temporal trends were similar (Fig. 2). For the *pfcr* K76T polymorphism, for which the mutant is associated with resistance to chloroquine, wild-type prevalence was higher than that reported in earlier surveys performed at 3 of the sites (7, 35), and this prevalence increased over time, such that, in 2017, >60% of samples were wild type at all sites and >90% were wild type at 6 of the sites. For *pfmdr1* N86Y and *pfmdr1* D1246Y, 80 to 100% of parasites were wild type at all study sites. As seen previously, the *pfmdr1* Y184F allele was polymorphic, but the prevalence of wild-type alleles did not change notably over time.

Prevalence of K13 polymorphisms. Of the 412 samples with successful sequencing of the *K13* propeller domain, 25 carried nonsynonymous polymorphisms, with 7




FIG 2 Prevalence of wild-type, mixed, and mutant alleles at the named sites over the indicated survey periods. The numbers above the site names represent survey periods (1, April 2016 to June 2016; 2, November 2016 to January 2017; 3, May 2017 to June 2017).

TABLE 1 Prevalence of K13 and copy number polymorphisms at the different sites in 2017

Site	N ^a	K13 candidate artemisinin resistance markers						Increased copy number		
		<i>Pfk13</i> A675V			<i>Pfk13</i> C469Y			N	<i>pfmdr1</i> (%)	<i>plasmepsin2</i> (%)
		Wild type (%)	Mixed (%)	Mutant (%)	Wild type (%)	Mixed (%)	Mutant (%)			
Agago	42	40 (95.2)	1 (2.4)	1 (2.4)	40 (95.2)	1 (2.4)	1 (2.4)	30	2 (6.7)	1 (3.3)
Amolatar	48	48 (100)	0	0	48 (100)	0	0	41	0	0
Arua	43	42 (97.7)	0	1 (2.3)	43 (100)	0	0	37	0	0
Jinja	48	48 (100)	0	0	48 (100)	0	0	37	0	1 (2.7)
Kanungu	48	48 (100)	0	0	48 (100)	0	0	45	0	0
Kole	47	46 (97.9)	0	1 (2.1)	46 (97.9)	0	1 (2.1)	31	0	0
Lamwo	43	39 (90.7)	0	4 (9.3)	41 (95.4)	1 (2.3)	1 (2.3)	35	0	0
Mubende	45	45 (100)	0	0	44 (97.8)	1 (2.2)	0	39	0	0
Tororo	48	48 (100)	0	0	48 (100)	0	0	40	0	0

^aN, number of samples successfully evaluated.

different mutations observed (Tables S2 and S3). Two single-nucleotide polymorphisms (SNPs) had a prevalence of >1%, A675V (2.0%) and C469Y (1.4%); both alleles were seen primarily at sites in northern Uganda (Table 1). The 675V mutation was seen in 7/128 (5.5%) samples from the 3 northernmost sites. The most common mutation previously reported in Africa, 578S, was seen in 3 (0.7%) samples.

Prevalence of parasites with increased *pfmdr1* and *plasmepsin2* gene copy numbers. Of 335 samples successfully assessed for copy number variation, only 2 (0.6%), both from Agago, had an increased *pfmdr1* copy number and 2 (0.6%; one each from Agago and Jinja) had increased *plasmepsin2* copy numbers (Table 1). Thus, consistent with prior reports (10), increased *pfmdr1* and *plasmepsin2* copy numbers were uncommon in Ugandan isolates.

Prevalence of drug resistance-mediating polymorphisms in folate pathway enzymes. As seen previously (7, 35), the prevalences of 5 mutations in *pfdhfr* (51I, 59R, and 108N) and *pfdhps* (437G and 540E) were high across Uganda (Fig. 2). Additional mutations associated with higher-level antifolate resistance (*pfdhfr* 164L and *pfdhps* 581G) were seen, with the prevalence of mixed or mutant *pfdhps* 581G at ~25 to 60% at sites in central and southwestern Uganda. However, the prevalences of *pfdhfr* 164L and *pfdhps* 581G mutant parasites did not increase over time at most sites.

DISCUSSION

In Uganda, treatment of malaria primarily with artemether-lumefantrine for the last decade has been associated with marked changes in *P. falciparum* genetic markers associated with drug sensitivity. To gain insight into recent trends across the country, we performed surveillance for relevant markers on 3 occasions in 2016 and 2017 at 10 sites representing a range of epidemiological settings. We found continued evolution toward wild-type transporter sequences, low prevalence of K13 mutations or amplified *pfmdr1* or *plasmepsin2*, and high prevalence of antifolate mutations. These results suggest increasing sensitivity of *P. falciparum* to chloroquine, a lack of resistance to artemisinins or major ACT partner drugs, and continued poor antimalarial efficacy of SP. Thus, in Uganda, *P. falciparum* appears to remain sensitive to the ACTs available to treat malaria, but the utility of antifolates to prevent malaria is in question.

The current evolution of transporter gene sequences in Uganda is not surprising. In Malawi, withdrawal of chloroquine in the 1990s was followed by increased prevalence of parasites with the wild-type *pfcr1* K76 allele, accompanied by improved chloroquine sensitivity (38, 39). Similar changes have been documented in other African countries, including Kenya (41) and Tanzania (42). In Uganda, reversion to wild-type *pfcr1* K76 and *pfmdr1* N86 and D1246 alleles was initially slow following chloroquine withdrawal, perhaps due to continued usage of chloroquine in the community and reasonably strong fitness of chloroquine-resistant parasites. Prior analyses showed a <10% prevalence of parasites with wild-type *pfcr1* K76 until 2012 in Tororo (7), but a steady increase in prevalence of the wild type in Tororo and two other sites since that time

(35). Reversion to wild-type *pfmdr1* N86 and D1246 alleles was also seen, with changes more rapid than those for *pfprt* K76T (7, 35). Our new results show continued selection of parasites that have wild-type sequences at key transporter alleles. Consistent with this finding, parasites collected in Tororo demonstrated increasing chloroquine *ex vivo* sensitivity over time (10). Remarkably, recent results suggest that chloroquine may soon again be a highly effective antimalarial in Uganda, although widespread use would likely reselect for resistant parasites.

Resistance to artemisinins, manifested as delayed parasite clearance after therapy or *in vitro*, is associated with polymorphisms in the *K13* gene. A total of 20 different *K13* propeller domain mutations have been associated with delayed clearance in southeast Asia (20), with resistance documented across the Greater Mekong Subregion (17, 18). In Africa, delayed clearance after therapy with ACTs (43) or when measured *in vitro* (22) appears to be very uncommon. Multiple *K13* mutations have been seen at low prevalence in African parasites, but many, including the most common polymorphism reported in Africa, A578S, have not been associated with delayed clearance (20). One mutation that has been associated with delayed clearance in southeast Asia, 675V, was seen in 2.0% of our study samples. This mutation was also noted in one sample collected in Rwanda in 2015 (44) and in one sample that showed delayed clearance *in vitro* in a recent study from northern Uganda (45). The clinical significance of this finding is uncertain, but in our study the polymorphism was geographically clustered in northern Uganda.

Amplification of *pfmdr1* has been associated with decreased sensitivity of *P. falciparum* to mefloquine (26) and lumefantrine (46) and amplification of *plasmepsin2* with decreased sensitivity to piperazine (27, 28). Amplification of *pfmdr1* (47, 48) and *plasmepsin2* (10) has been uncommon in previous studies from Uganda, as also seen in our new results. These results are reassuring, as they suggest continued strong efficacy of important ACT partner drugs, consistent with excellent efficacy for leading ACTs in recent trials (21, 49).

SP was abandoned as a treatment for malaria due to widespread resistance in *P. falciparum*, mediated by well-characterized mutations in the *pfdhfr* and *pfdhps* genes (31), however, SP remains the standard of care for IPTp in areas of Africa where malaria is endemic (5). SP is also increasingly used for seasonal malaria chemoprophylaxis, whereby treatment courses of SP plus amodiaquine are provided monthly during the rainy season in parts of west and central Africa (4). We found that all 5 *pfdhfr* and *pfdhps* mutations commonly associated with SP resistance in Africa remain widespread in Uganda. In addition, the *pfdhfr* 164L and *pfdhps* 581G mutations, which predict higher-level resistance, were seen in samples from many sites. These results suggest that, in Uganda, the antimalarial efficacy of SP for IPTp or other indications is poor, consistent with results of recent clinical studies (5, 36, 50). Furthermore, while SP plus amodiaquine appears to be efficacious for malaria chemoprevention in areas where the *pfdhps* 540E mutation is absent (4), this regimen is unlikely to be effective in Uganda. Other regimens for chemoprevention, in particular the ACT dihydroartemisinin-piperazine, are under study for intermittent preventive therapy (IPT) in pregnancy (50, 51) and in children (3, 52). Our data suggest continued good antimalarial activity of dihydroartemisinin-piperazine in Uganda, although loss of activity of this regimen in Cambodia (29, 30) is concerning.

Our study had important limitations. First, we studied convenience samples collected across Uganda; we cannot be sure that our results are representative of all parasites from the study areas. Second, we assessed only polymorphisms already associated with resistance to antimalarials. Additional genetic changes in *P. falciparum* likely impact sensitivity to various antimalarial agents. Although it is difficult to identify new resistance mediators in highly diverse clinical isolates, broader deep sequencing approaches should shed light on additional polymorphisms contributing to drug sensitivity. Third, for some uncommon markers we only evaluated the most recent available samples, so were unable to characterize temporal trends.

In summary, in studies from a range of sites in Uganda, we identified consistent

changes in *P. falciparum* genetic markers associated with drug sensitivity over time. Importantly, markers associated with resistance to artemisinins or key ACT partner drugs were not seen. Markers indicating resistance to antifolates had continued high prevalence. These findings suggest that continued use of leading ACTs to treat malaria in Uganda is warranted, but that continued surveillance for markers associated elsewhere with ACT resistance is a high priority.

MATERIALS AND METHODS

We selected 10 sites to represent different regions of Uganda with varied malaria transmission intensity and epidemiology (Fig. 1). At each site, as part of routine care, health care personnel evaluated children 6 months to 10 years of age with clinical syndromes suggestive of malaria using either Giemsa-stained blood smears or histidine-rich protein 2 (HRP2)-based rapid diagnostic tests, following national guidelines and depending on local availability of these tests. Consecutive children diagnosed with malaria and their parents or guardians were approached for enrollment, and, if consent was obtained, blood was collected as 4 blood spots dried on Whatman 3MM filter paper. Filter paper samples were stored in zipper storage bags with desiccant at room temperature and transported to our laboratory in Kampala for evaluation. This study was approved by the Makerere University Research and Ethics Committee, the Uganda National Council of Science and Technology, and by the University of California, San Francisco Committee on Human Research.

Genomic DNA was extracted from blood spots using Chelex 100, as previously described (53). *Pfmdr1*, *pfcr1*, *pfdhfr*, and *pfdhps* polymorphisms of interest were characterized by PCR and ligase detection reaction-fluorescent microsphere assays, as previously described (54), with minor modification to incorporate nested PCR (48). Copy number variations for *pfmdr1* and *plasmepsin2* were assessed by quantitative PCR (qPCR), and the *K13* propeller domain was amplified and sequenced, all as previously described (10).

Data availability. Nucleotide sequences are available in the GenBank database under the accession numbers [MH788997](https://doi.org/10.1093/nar/nkz111) to [MH789408](https://doi.org/10.1093/nar/nkz111).

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at <https://doi.org/10.1128/AAC.01818-18>.

SUPPLEMENTAL FILE 1, PDF file, 0.4 MB.

ACKNOWLEDGMENTS

This study was supported by funding from the National Institutes of Health (grants AI089674 and AI075045).

We thank the study participants, their parents and guardians, and the clinical staffs of the health care facilities for their cooperation.

REFERENCES

- Rosenthal PJ. 2013. The interplay between drug resistance and fitness in malaria parasites. *Mol Microbiol* 89:1025–1038. <https://doi.org/10.1111/mmi.12349>.
- Yeka A, Gasasira A, Mpimbaza A, Achan J, Nankabirwa J, Nsoby S, Staedke SG, Donnelly MJ, Wabwire-Mangen F, Talisuna A, Dorsey G, Kanya MR, Rosenthal PJ. 2012. Malaria in Uganda: challenges to control on the long road to elimination: I. Epidemiology and current control efforts. *Acta Trop* 121:184–195. <https://doi.org/10.1016/j.actatropica.2011.03.004>.
- Nankabirwa JI, Wandera B, Amuge P, Kiwanuka N, Dorsey G, Rosenthal PJ, Brooker SJ, Staedke SG, Kanya MR. 2014. Impact of intermittent preventive treatment with dihydroartemisinin-piperazine on malaria in Ugandan schoolchildren: a randomized, placebo-controlled trial. *Clin Infect Dis* 58:1404–1412. <https://doi.org/10.1093/cid/ciu150>.
- Cissé B, Ba EH, Sokhna C, NDiaye JL, Gomis JF, Dial Y, Pitt C, NDiaye M, Cairns M, Faye E, NDiaye M, Lo A, Tine R, Faye S, Faye B, Sy O, Konate L, Kouevijidin E, Flach C, Faye O, Trape J-F, Sutherland C, Fall FB, Thior PM, Faye OK, Greenwood B, Gaye O, Milligan P. 2016. Effectiveness of seasonal malaria chemoprevention in children under ten years of age in Senegal: a stepped-wedge cluster-randomised trial. *PLoS Med* 13:e1002175. <https://doi.org/10.1371/journal.pmed.1002175>.
- Desai M, Hill J, Fernandes S, Walker P, Pell C, Gutman J, Kayentao K, Gonzalez R, Webster J, Greenwood B, Cot M, ter Kuile FO. 2018. Prevention of malaria in pregnancy. *Lancet Infect Dis* 18:e119. [https://doi.org/10.1016/S1473-3099\(18\)30064-1](https://doi.org/10.1016/S1473-3099(18)30064-1).
- Blasco B, Leroy D, Fidock DA. 2017. Antimalarial drug resistance: linking *Plasmodium falciparum* parasite biology to the clinic. *Nat Med* 23:917. <https://doi.org/10.1038/nm.4381>.
- Mbogo GW, Nankoberanyi S, Tukwasibwe S, Baliraine FN, Nsoby SL, Conrad MD, Arinaitwe E, Kanya M, Tappero J, Staedke SG, Dorsey G, Greenhouse B, Rosenthal PJ. 2014. Temporal changes in prevalence of molecular markers mediating antimalarial drug resistance in a high malaria transmission setting in Uganda. *Am J Trop Med Hyg*:54–56. <https://doi.org/10.4269/ajtmh.13-0647>.
- Nsoby SL, Dokomajilar C, Joloba M, Dorsey G, Rosenthal PJ. 2007. Resistance-mediating *Plasmodium falciparum* *pfcr1* and *pfmdr1* alleles after treatment with artesunate-amodiaquine in Uganda. *Antimicrob Agents Chemother* 51:3023–3025. <https://doi.org/10.1128/AAC.00012-07>.
- Humphreys G, Merinopoulos I, Ahmed J, Whitty C, Mutabingwa T, Sutherland C, Hallett R. 2007. Amodiaquine and artemether-lumefantrine select distinct alleles of the *Plasmodium falciparum* *mdr1* gene in Tanzanian children treated for uncomplicated malaria. *Antimicrob Agents Chemother* 51:991–997. <https://doi.org/10.1128/AAC.00875-06>.
- Rasmussen SA, Ceja FG, Conrad MD, Tumwebaze PK, Byaruhanga O, Katairo T, Nsoby SL, Rosenthal PJ, Cooper RA. 2017. Changing antimalarial drug sensitivities in Uganda. *Antimicrob Agents Chemother* 61:e01516-17. <https://doi.org/10.1128/AAC.01516-17>.
- Sisowath C, Strömberg J, Mårtensson A, Msellem M, Obondo C, Björkman A, Gil JP. 2005. In vivo selection of *Plasmodium falciparum* *pfmdr1* 86N coding alleles by artemether-lumefantrine (Coartem). *J Infect Dis* 191:1014–1017. <https://doi.org/10.1086/427997>.
- Zongo I, Dorsey G, Rouamba N, Tinto H, Dokomajilar C, Guiguemde RT,

- Rosenthal PJ, Ouedraogo JB. 2007. Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. *Lancet* 369:491–498. [https://doi.org/10.1016/S0140-6736\(07\)60236-0](https://doi.org/10.1016/S0140-6736(07)60236-0).
13. Baliraine FN, Rosenthal PJ. 2011. Prolonged selection of *pfmdr1* polymorphisms after treatment of falciparum malaria with artemether-lumefantrine in Uganda. *J Infect Dis* 204:1120–1124. <https://doi.org/10.1093/infdis/jir486>.
 14. Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, Price RN, Mårtensson A, Rosenthal PJ, Dorsey G, Sutherland CJ, Guérin P, Davis TME, Ménard D, Adam I, Ademowo G, Arze C, Baliraine FN, Berens-Riha N, Björkman A, Borrmann S, Checchi F, Desai M, Dhorda M, Djimé AA, El-Sayed BB, Eshetu T, Eyase F, Falade C, Faucher JF, Fröberg G, Grivoyannis A, Hamour S, Houzé S, Johnson J, Kamugisha E, Kariuki S, Kiechel JR, Kironde F, Kofoed PE, LeBras J, Malmberg M, Mwai L, Ngasala B, Nosten F, Nsoya SL, Nzila A, Oguike M, Otienoburu SD, Ogutu B, Ouedraogo JB, Piola P, Rombo L, Schramm B, Somé AF, Thwing J, Ursing J, Wong RPM, Zeynudin A, Zongo I, Plowe CV, Sibley CH. 2014. Polymorphisms in *Plasmodium falciparum* chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for *P. falciparum* malaria after artemether-lumefantrine and artesunate-amodiaquine. *Am. J Trop Med Hyg* 91:833–843. <https://doi.org/10.4269/ajtmh.14-0031>.
 15. Dondorp AM, Nosten F, Yi P, Das D, Phyto AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NPJ, Lindegardh N, Socheat D, White NJ. 2009. Artemisinin resistance in *Plasmodium falciparum* malaria. *N Engl J Med* 361:455–467. <https://doi.org/10.1056/NEJMoa0808859>.
 16. Witkowski B, Amaratunga C, Khim N, Sreng S, Chim P, Kim S, Lim P, Mao S, Sopha C, Sam B, Anderson JM, Duong S, Chuor CM, Taylor WRJ, Suon S, Mercereau-Puijalon O, Fairhurst RM, Menard D. 2013. Novel phenotypic assays for the detection of artemisinin-resistant *Plasmodium falciparum* malaria in Cambodia: in-vitro and ex-vivo drug-response studies. *Lancet Infect Dis* 13:1043–1049. [https://doi.org/10.1016/S1473-3099\(13\)70252-4](https://doi.org/10.1016/S1473-3099(13)70252-4).
 17. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Mao S, Sam B, Sopha C, Chuor CM, Nguon C, Sovannaroeth S, Pukrittayakamee S, Jittamala P, Chotivanich K, Chutasmit K, Suchatsoonthorn C, Runcharoen R, Hien TT, Thuy-Nhien NT, Thanh NV, Phu NH, Htut Y, Han KT, Aye KH, Mokuolu OA, Olaosebikan RR, Folaranmi OO, Mayxay M, Khanthavong M, Hongvanthong B, Newton PN, Onyamboko MA, Fanello CI, Tshetu AK, Mishra N, Valecha N, Phyto AP, Nosten F, Yi P, Tripura R, Borrmann S, Bashraheil M, Peshu J, Faiz AB, Ghose A, Hossain MA, Samad R, Rahman MR, Hasan MM, Islam A, Miotto O, Amato R, MacInnis B, Stalker J, Kwiatkowski DP, Bozdech Z, Jeeyapant A, Cheah PY, Sakulthaew T, Chalk J, Intharabut B, Silamut K, Lee SJ, Vihokhern B, Kunasol C, Imwong M, Tarning J, Taylor WJ, Yeung S, Woodrow CJ, Flegg JA, Das D, Smith J, Venkatesan M, Plowe CV, Stepniewska K, Guerin JP, Dondorp AM, Day NPJ, White NJ. 2014. Spread of artemisinin resistance in *Plasmodium falciparum* malaria. *N Engl J Med* 371:411–423. <https://doi.org/10.1056/NEJMoa1314981>.
 18. Imwong M, Suwannasin K, Kunasol C, Sutawong K, Mayxay M, Rekol H, Smithuis FM, Hlaing TM, Tun KM, van der Pluijm RW, Tripura R, Miotto O, Menard D, Dhorda M, Day NPJ, White NJ, Dondorp AM. 2017. The spread of artemisinin-resistant *Plasmodium falciparum* in the Greater Mekong subregion: a molecular epidemiology observational study. *Lancet Infect Dis* 17:491–497. [https://doi.org/10.1016/S1473-3099\(17\)30048-8](https://doi.org/10.1016/S1473-3099(17)30048-8).
 19. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois A-C, Khim N, Kim S, Duru V, Bouchier C, Ma L, Lim P, Leang R, Duong S, Sreng S, Suon S, Chuor CM, Bout DM, Ménard S, Rogers WO, Genton B, Fandeur T, Miotto O, Ringwald P, Bras JL, Berry A, Barale CJ, Fairhurst RM, Benoit-Vical F, Mercereau-Puijalon O, Ménard M. 2014. A molecular marker of artemisinin-resistant *Plasmodium falciparum* malaria. *Nature* 505:50–55. <https://doi.org/10.1038/nature12876>.
 20. WWARN *K13* Genotype-Phenotype Study Group. Association of mutations in the *Plasmodium falciparum* *Kelch13* gene (Pf3D7_1343700) with parasite clearance rates after artemisinin-based treatments—a WWARN individual patient data meta-analysis. *BMC Infect Dis*, in press.
 21. Yeka A, Kigozi R, Conrad MD, Lugemwa M, Okui P, Katureebe C, Belay K, Kapella BK, Chang MA, Kanya MR, Staedke SG, Dorsey G, Rosenthal PJ. 2016. Artesunate/amodiaquine versus artemether/lumefantrine for the treatment of uncomplicated malaria in Uganda: a randomized trial. *J Infect Dis* 213:1134–1142. <https://doi.org/10.1093/infdis/jiv551>.
 22. Cooper RA, Conrad MD, Watson QD, Huelzo SJ, Ninsiima H, Tumwebaze P, Nsoya SL, Rosenthal PJ. 2015. Lack of artemisinin resistance in *Plasmodium falciparum* in Uganda based on parasitological and molecular assays. *Antimicrob Agents Chemother* 59:5061–5064. <https://doi.org/10.1128/AAC.00921-15>.
 23. Conrad MD, Bigira V, Kapiji J, Muhindo M, Kanya MR, Havlir DV, Dorsey G, Rosenthal PJ. 2014. Polymorphisms in *K13* and falcipain-2 associated with artemisinin resistance are not prevalent in *Plasmodium falciparum* isolated from Ugandan children. *PLoS One* 9:e105690. <https://doi.org/10.1371/journal.pone.0105690>.
 24. Taylor SM, Parobek CM, Deconti DK, Kayentao K, Coulibaly SO, Greenwood BM, Tagbor H, Williams J, Bojang K, Njie F, Desai M, Kariuki S, Gutman J, Mathanga DP, Mårtensson A, Ngasala B, Conrad MD, Rosenthal PJ, Tshetu AK, Moormann AM, Vulule JM, Doumbo OK, Ter Kuile FO, Meshnick SR, Bailey JA, Juliano JJ. 2015. Absence of putative artemisinin resistance mutations among *Plasmodium falciparum* in Sub-Saharan Africa: a molecular epidemiologic study. *J Infect Dis* 211:680–688. <https://doi.org/10.1093/infdis/jiu467>.
 25. Talundzic E, Ndiaye YD, Deme AB, Olsen C, Patel DS, Biliya S, Daniels R, Vannberg FO, Volkman SK, Udhayakumar VJA, Ndiaye D. 2017. The molecular epidemiology of *Plasmodium falciparum* *kelch13* mutations in Senegal using targeted amplicon deep sequencing. *Antimicrob Agents Chemother* 61:e02116-16. <https://doi.org/10.1128/AAC.02116-16>.
 26. Price RN, Uhlemann A-C, Brockman A, McGready R, Ashley E, Phaipun L, Patel R, Laing K, Loareesuwan S, White NJ, Nosten F, Krishna S. 2004. Mefloquine resistance in *Plasmodium falciparum* and increased *Pfmdr1* gene copy number. *Lancet* 364:438–447. [https://doi.org/10.1016/S0140-6736\(04\)16767-6](https://doi.org/10.1016/S0140-6736(04)16767-6).
 27. Amato R, Lim P, Miotto O, Amaratunga C, Dek D, Pearson RD, Almagro-Garcia J, Neal AT, Sreng S, Suon S, Drury E, Jyothi D, Stalker J, Kwiatkowski DP, Fairhurst RM. 2017. Genetic markers associated with dihydroartemisinin-piperaquine failure in *Plasmodium falciparum* malaria in Cambodia: a genotype-phenotype association study. *Lancet Infect Dis* 17:164–173. [https://doi.org/10.1016/S1473-3099\(16\)30409-1](https://doi.org/10.1016/S1473-3099(16)30409-1).
 28. Witkowski B, Duru V, Khim N, Ross LS, Saintpierre B, Beghain J, Chy S, Kim S, Ke S, Kloeung N, Eam R, Khean C, Ken M, Loch K, Bouillon A, Domergue A, Ma L, Bouchier C, Leang R, Huy R, Nuel G, Barale CJ, Legrand E, Ringwald P, Fidock DA, Mercereau-Puijalon O, Ariey F, Ménard D. 2017. A surrogate marker of piperaquine-resistant *Plasmodium falciparum* malaria: a phenotype-genotype association study. *Lancet Infect Dis* 17:174–183. [https://doi.org/10.1016/S1473-3099\(16\)30415-7](https://doi.org/10.1016/S1473-3099(16)30415-7).
 29. Spring MD, Lin JT, Manning JE, Vanachayangkul P, Somethy S, Bun R, Se Y, Chann S, Ittiverakul M, Sia-ngam P, Kuntawunginn W, Arsanok M, Buathong N, Chaorattanakawee S, Gosi S, Ta-aksorn W, Chanarat N, Sundrakes S, Kong N, Heng TK, Nou S, Teja-isavadharm P, Pichyangkul S, Phann ST, Balasubramanian S, Juliano SJ, Meshnick SR, Chour CM, Prom S, Lanteri CA, Lon C, Saunders DL. 2015. Dihydroartemisinin-piperaquine failure associated with a triple mutant including *kelch13 C580Y* in Cambodia: an observational cohort study. *Lancet Infect Dis* 15:683–691. [https://doi.org/10.1016/S1473-3099\(15\)70049-6](https://doi.org/10.1016/S1473-3099(15)70049-6).
 30. Amaratunga C, Lim P, Suon S, Sreng S, Mao S, Sopha C, Sam B, Dek D, Try V, Amato R, Blessborn D, Song L, Tullo GS, Fay MP, Anderson JM, Tarning J, Fairhurst RM. 2016. Dihydroartemisinin-piperaquine resistance in *Plasmodium falciparum* malaria in Cambodia: a multisite prospective cohort study. *Lancet Infect Dis* 16:357–365. [https://doi.org/10.1016/S1473-3099\(15\)00487-9](https://doi.org/10.1016/S1473-3099(15)00487-9).
 31. Gregson A, Plowe CV. 2005. Mechanisms of resistance of malaria parasites to antifolates. *Pharmacol Rev* 57:117–145. <https://doi.org/10.1124/pr.57.1.4>.
 32. Naidoo I, Roper C. 2013. Mapping ‘partially resistant’, ‘fully resistant’, and ‘super resistant’ malaria. *Trends Parasitol* 29:505–515. <https://doi.org/10.1016/j.pt.2013.08.002>.
 33. Pearce RJ, Pota H, Evehe M-SB, Bâ E-H, Mombo-Ngoma G, Malisa AL, Ord R, Inojosa W, Matondo A, Diallo DAJ, Mbacham W, Van den Broek I, Swarthout TD, Getachew A, Dejene S, Grobusch MP, Njie F, Dunyo S, Kweku M, Owusu-Agyei S, Chandramohan D, Bonnet M, Guthmann JP, Clarke S, Barnes KI, Streat E, Katokele ST, Uusiku P, Agboghoro MA, Elegba OY, Cissé B, A-Elbasit IE, Giha HA, Kachur SP, Lynch C, Rwakimari JB, Chanda P, Hawela M, Sharp B, Naidoo I, Roper C. 2009. Multiple origins and regional dispersal of resistant *dhps* in African *Plasmodium falciparum* malaria. *PLoS Med* 6:e1000055. <https://doi.org/10.1371/journal.pmed.1000055>.
 34. Lynch C, Pearce R, Pota H, Cox J, Abeku TA, Rwakimari J, Naidoo I, Tibenderana J, Roper C. 2008. Emergence of a *dhfr* mutation conferring high-level drug resistance in *Plasmodium falciparum* populations from

- southwest Uganda. *J Infect Dis* 197:1598–1604. <https://doi.org/10.1086/587845>.
35. Tumwebaze P, Tukwasibwe S, Taylor A, Conrad M, Ruhamyankaka E, Asua V, Walakira A, Nankabirwa J, Yeka A, Staedke SG, Greenhouse B, Nsobya SL, Kanya MR, Dorsey G, Rosenthal PJ. 2016. Changing antimalarial drug resistance patterns identified by surveillance at three sites in Uganda. *J Infect Dis* 215:631–635. <https://doi.org/10.1093/infdis/jiw614>.
 36. Braun V, Rempis E, Schnack A, Decker S, Rubaihayo J, Tumwesigye NM, Theuring S, Harms G, Busingye P, Mockenhaupt FPJM. 2015. Lack of effect of intermittent preventive treatment for malaria in pregnancy and intense drug resistance in western Uganda. *Malar J* 14:372. <https://doi.org/10.1186/s12936-015-0909-7>.
 37. Gesase S, Gosling RD, Hashim R, Ord R, Naidoo I, Madebe R, Mosha JF, Joho A, Mandia V, Mrema H, Mapunda E, Savael Z, Lemnge M, Mosha FW, Greenwood B, Roper C, Chandramohan D. 2009. High resistance of *Plasmodium falciparum* to sulphadoxine/pyrimethamine in northern Tanzania and the emergence of *dhps* resistance mutation at Codon 581. *PLoS One* 4:e4569. <https://doi.org/10.1371/journal.pone.0004569>.
 38. Kublin JG, Cortese JF, Njunju EM, Mukadam RAG, Wirima JJ, Kazembe PN, Djimé AA, Kouriba B, Taylor TE, Plowe CV. 2003. Reemergence of chloroquine-sensitive *Plasmodium falciparum* malaria after cessation of chloroquine use in Malawi. *J Infect Dis* 187:1870–1875. <https://doi.org/10.1086/375419>.
 39. Laufer MK, Hesing PC, Eddington ND, Masonga R, Dzinjalama FK, Takala SL, Taylor TE, Plowe CV. 2006. Return of chloroquine antimalarial efficacy in Malawi. *N Engl J Med* 355:1959–1966. <https://doi.org/10.1056/NEJMoa062032>.
 40. Bukirwa H, Yeka A, Kanya MR, Talisuna A, Banek K, Bakyaite N, Rwakimari JB, Rosenthal PJ, Wabwire-Mangen F, Dorsey G, Staedke SG. 2006. Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. *PLoS Clin Trial* 1:e7. <https://doi.org/10.1371/journal.pctr.0010007>.
 41. Eyase FL, Akala HM, Ingasia L, Cheruyiot A, Omondi A, Okudo C, Juma D, Yeda R, Andagalu B, Wanja E, Kamau E, Schnabel D, Bulimo W, Waters NC, Walsh DS, Johnson JD. 2013. The role of *pfmdr1* and *pfcr1* in changing chloroquine, amodiaquine, mefloquine and lumefantrine susceptibility in western-Kenya *P. falciparum* samples during 2008–2011. *PLoS One* 8:e64299. <https://doi.org/10.1371/journal.pone.0064299>.
 42. Malmberg M, Ngasala B, Ferreira PE, Larsson E, Jovel I, Hjalmarsson A, Petzold M, Premji Z, Gil JP, Björkman A, Martensson A. 2013. Temporal trends of molecular markers associated with artemether-lumefantrine tolerance/resistance in Bagamoyo district, Tanzania. *Malar J* 12:103. <https://doi.org/10.1186/1475-2875-12-103>.
 43. WWARN Artemisinin Based Combination Therapy (ACT) Africa Baseline Study Group, Dahal P, d'Alessandro U, Dorsey G, Guerin PJ, Nsanzabana C, Price RN, Sibley CH, Stepniewska K, Talisuna AO. 2015. Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient data. *BMC Med* 13:212. <https://doi.org/10.1186/s12916-015-0445-x>.
 44. Tacoli C, Gai PP, Bayingana C, Sifft K, Geus D, Ndoli J, Sendegeya A, Gahutu JB, Mockenhaupt FP. 2016. Artemisinin resistance-associated *K13* polymorphisms of *Plasmodium falciparum* in southern Rwanda, 2010–2015. *Am J Trop Med Hyg* 95:1090–1093. <https://doi.org/10.4269/ajtmh.16-0483>.
 45. Ikeda M, Kaneko M, Tachibana S-I, Balikagala B, Sakurai-Yatsushiro M, Yatsushiro S, Takahashi N, Yamauchi M, Sekihara M, Hashimoto M, Katuro OT, Olia A, Obwoya PS, Auma MA, Anywar DA, Odongo-Aginya El, Okello-Onen J, Hirai M, Ohashi J, Palacpac NMQ, Kataoka M, Tsuboi T, Kimura E, Horii T, Mita T. 2018. Artemisinin-resistant *Plasmodium falciparum* with high survival rates, Uganda, 2014–2016. *Emerg Infect Dis* 24:718. <https://doi.org/10.3201/eid2404.170141>.
 46. Price RN, Uhlemann A-C, van Vugt M, Brockman A, Hutagalung R, Nair S, Nash D, Singhasivanon P, Anderson TJ, Krishna S, White NJ, Nosten F. 2006. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant *Plasmodium falciparum* malaria. *Clin Infect Dis* 42:1570–1577. <https://doi.org/10.1086/503423>.
 47. Dokomajilar C, Nsobya SL, Greenhouse B, Rosenthal PJ, Dorsey G. 2006. Selection of *Plasmodium falciparum pfmdr1* alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. *Antimicrob Agents Chemother* 50:1893–1895. <https://doi.org/10.1128/AAC.50.5.1893-1895.2006>.
 48. Conrad MD, LeClair N, Arinaitwe E, Wanzira H, Kakuru A, Bigira V, Muhindo M, Kanya MR, Tappero JW, Greenhouse B, Dorsey G, Rosenthal PJ. 2014. Comparative impacts over 5 years of artemisinin-based combination therapies on *Plasmodium falciparum* polymorphisms that modulate drug sensitivity in Ugandan children. *J Infect Dis* 210:344–353. <https://doi.org/10.1093/infdis/jiu141>.
 49. Sagara I, Beavogui AH, Zongo I, Borghini-Fuhrer I, Fofana B, Traore A, Diallo N, Diakite H, Togo AH, Koumare S, Keita M, Camara D, Somé AF, Coulibaly AS, Traore OB, Dama S, Goita S, Djimde M, Bamadio A, Dara N, Maiga H, Sidibe B, Dao F, Coulibaly M, Alhousseini ML, Niangaly H, Sangare B, Diarra M, Coumare S, Kabore MJT, Ouattara SM, Barry A, Kargougou D, Diarra A, Henry N, Soré H, Bougouma EC, Thera I, Compaore YD, Sutherland CJ, Sylla MM, Nikiema F, Diallo MS, Dicko A, Picot S, Borrmann S, Duparc S, Miller RM, Doumbo OK, Shin J, Gil PJ, Björkman A, Ouedraogo JB, Sirima SB, Djimde AA. 2018. Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. *Lancet* 391:1378–1390. [https://doi.org/10.1016/S0140-6736\(18\)30291-5](https://doi.org/10.1016/S0140-6736(18)30291-5).
 50. Desai M, Gutman J, L'lanziva A, Otieno K, Juma E, Kariuki S, Ouma P, Were V, Laserson K, Katana A, Williamson J, ter Kuile FO. 2015. Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial. *Lancet* 386:2507–2519. [https://doi.org/10.1016/S0140-6736\(15\)00310-4](https://doi.org/10.1016/S0140-6736(15)00310-4).
 51. Kakuru A, Jagannathan P, Muhindo MK, Natureeba P, Awori P, Nakalembe M, Opira B, Olwoch P, Ategeka J, Nayebare P, Clark TD, Feeney ME, Charlebois ED, Rizzuto G, Muehlenbachs A, Havlir DV, Kanya MR, Dorsey G. 2016. Dihydroartemisinin-piperaquine for the prevention of malaria in pregnancy. *N Engl J Med* 374:928–939. <https://doi.org/10.1056/NEJMoa1509150>.
 52. Bigira V, Kapisi J, Clark TD, Kinara S, Mwangwa F, Muhindo MK, Osterbauer B, Aweeka FT, Huang L, Achan J, Havlir DV, Rosenthal PJ, Kanya MR, Dorsey G. 2014. Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial. *PLoS Med* 11:e1001689. <https://doi.org/10.1371/journal.pmed.1001689>.
 53. Asua V, Tukwasibwe S, Conrad M, Walakira A, Nankabirwa J, Mugenyi L, Kanya MR, Nsobya SL, Rosenthal PJ. 2017. *Plasmodium* species infecting children presenting with malaria in Uganda. *Am J Trop Med Hyg* 97:753–757. <https://doi.org/10.4269/ajtmh.17-0345>.
 54. LeClair NP, Conrad MD, Baliraine FN, Nsanzabana C, Nsobya SL, Rosenthal PJ. 2013. Optimization of a ligase detection reaction-fluorescent microsphere assay for characterization of resistance-mediating polymorphisms in African samples of *Plasmodium falciparum*. *J Clin Microbiol* 51:2564–2570. <https://doi.org/10.1128/JCM.00904-13>.